No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes

Archives of Neurology

Volumn 54, Issue 3, 1997, Pages 273-277

  Corder, Elizabeth H ^a,c   Jelic, Vesna ^a   Bosun, Hans ^b   Lannfelt, Lars ^b   Valind, Sven ^c   Winblad, Bengt ^d   Nordberg, Agneta ^e  

^a Division of Geriatric Medicine   (Sweden)

^b Division of Nicotine Research   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d Dufee University   (United States)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; DNA; FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ADULT; AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; GENOTYPE; GLUCOSE METABOLISM; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0030907745     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.1997.00550150035013     Document Type: Article

References (26)

1. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622-628.
2. Utermann G, Langenbeck U, Beisiegel U, Weber W. Genetics of the apolipoprotein E system in man. Am J Hum Genet. 1980:32:339-347.
3. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high avidity binding to beta-amyloid and increased frequency of type-4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA. 1993:90:1977-1981.
4. Saunders AM, Strittmatter WJ, Schmechel DE, et al. Association of apolipoprotein E allele t4 with late onset familial and sporadic Alzheimer's disease. Neurology. 1993:43:1467-1472.
5. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993:261:921-923.
6. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994:7:180-184.
7. Kuusisto J, Koivisto K, Kervinen K, et al. Association of apolipoprotein E phenotypes with late onset Alzheimer's disease: population based study. BMJ. 1994; 309:636-638.
8. Feskens EJM, Havekes LM, Kalmijn S, de Knijff P, Launer U, Kromhout D. Apolipoprotein e4 allele and cognitive decline in elderly men. BMJ. 1994;398: 1202-1206.
9. Basun H, Grut M, Winblad B, Lannfelt L. Apolipoprotein ε4 allele and disease progression in patients with late-onset Alzheimer's disease. Neurosci Lett. 1995; 183:32-34.
10. Dal Forno G, Rasmusson X, Brandt J, et al. Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. Arch Neurol. 1996:53:345-350.
11. Corder EH, Saunders AM, Strittmatter WJ, et al. Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. Neurology. 1995:45:1323-1328.
12. Norrmann J, Brookes AJ, Yates C, St Clair D. Apolipoprotein E genotype and its effect on duration and severity of early and late onset Alzheimer's disease. Br J Psychiatry. 1995;167:533-536.
13. Rappoport SI. Positron emission tomography in Alzheimer's disease in relation to disease pathogenesis: a critical review. Cererjrovasc Brain Metab Rev. 1991:3:297-335.
14. Nordberg A. Clinical studies in Alzheimer patients with positron emission tomography. Behav Brain Res. 1993:57:215-234.
15. Mielke R, Herholz K, Grand M, Kessler J, Heiss WD. Clinical deterioration in probable Alzheimer's disease correlates with progressive metabolic impairment of association areas. Dementia. 1994:5:36-41.
16. Minoshima S, Foster ML, Kuhl DE. Posterior cingulate cortex in Alzheimer's disease. Lancet. 1994;344:895.
17. Pietrini P, Azari NP, Grady CL, et al. Pattern of cerebral metabolic interactions in a subject with isolated amnesia at risk for Alzheimer's disease: a longitudinal evaluation. Dementia. 1993;4:94-101.
18. Kennedy AM, Frackowiak RSJ, Newman SK, et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci Lett. 1995:186:17-20.
19. Nordberg A, Viitanen M, Almkvist O, et al. Longitudinal positron emission tomographic studies in families with chromosome 14 and 21 encoded Alzheimer's disease. In: Iqbal H, Mortimer JA, Winblad B, Wisniewski HM, eds. Research Advances in Alzheimer's Disease and Related Disorders. New York, NY: John Wiley & Sons Inc; 1995:243-249.
20. Small GW, Mazziotta JC, Collins MT, et al. The effect of apolipoprotein E type 4 allele on cerebral glucose metabolism in relatives at risk for Alzheimer disease. JAMA. 1995:273:942-947.
21. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the ε4 allele for apolipoprotein E. N Engt J Med. 1996:334:752-758.
22. Folstein MF, Folstein SE, McHugh PR. 'Mini-Mental State': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975:12:189-198.
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984:34:939-944.
24. Clark RF, Hutton M, Fuldner R, et al. The structure of the chromosome 14 Alzheimer's disease gene, S182, and identification of six novel mutations in early onset AD families. Nat Genet. 1995:11:219-222.
25. Patlak CS, Blasberg JD, Fenstermacher JD. Graphical evaluation of blood-tobrain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1-7.
26. Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein ε4 allele as predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc Natl Acad Sci USA. 1995:92:12260-12264.